RxDoctor Payments Data

John Benavides, DO

Pain Medicine · Paris, TXNPI 1750311726

Payments from drug & device makers

$2,268in general payments, 2019–2025

Across 51 payments — averaging $44.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$775
  • SPR Therapeutics, Inc$424
  • Vertos Medical, Inc.$366
  • Abbott$212
  • GRT US Holding, Inc.$144
  • Medtronic$128
  • plus $219 from 8 others

What the payments were for

  • Food & beverage$2,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,268 in reported general payments places this provider in the 40th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$297,242
Medicare patients
658
Services billed
3,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen4,210$125,821
Fentanyl270$24,771
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen708$24,094
OxycontinOxycodone Hcl50$21,204
Xtampza ErOxycodone Myristate18$17,665
BelsomraSuvorexant19$8,273
Morphine Sulfate ErMorphine Sulfate307$8,242
Oxycodone Hcl277$6,870
Hydromorphone Hcl259$4,925
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$3,716
Pregabalin238$1,865
Acetaminophen-CodeineAcetaminophen With Codeine79$1,503
Buprenorphine Hcl22$1,475
Methadone Hcl93$1,441
Lidocaine13$1,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$32$17,66518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →